[SaNOtize in Business Wire] Phase 3 Clinical Trial Confirms SaNOtize’s Breakthrough Treatment is 99% Effective Against COVID-19; Receives Regulatory Approval in India

VANCOUVER, British Columbia & MUMBAI, India–(BUSINESS WIRE)–Canadian pharmaceutical company SaNOtize Research & Development Corp., (SaNOtize), and Glenmark Pharmaceuticals Limited (Glenmark), a global, innovation-driven pharmaceutical company, today announced successful results of Phase 3 clinical trials and approval from India’s drug regulator for the treatment of adult patients with COVID-19 who have a risk of progression of the disease.

Read more here.